Identified Hapten Patents (Class 436/822)
-
Patent number: 4762781Abstract: New antibodies capable of specifically identifying hapten groups, characterized by the fact that said hapten groups correspond to the formula:--NH--(CH.sub.2).sub.n --NH--Hapt.in whichn is a whole number between 4 and 6, and Hapt. is the residue of the hapten molecule of formula Hapt. --NH.sub.2 (--NH.sub.2 being a primary amine group) or of formula Hapt..dbd.NH (.dbd.NH being the imine of a guanidine type group);their preparation through immunization using immunogens of the formula:[M --NH--(CH.sub.2).sub.n NH--Hapt.].sub.xand their application, particularly in visualizing and determining the quantity of haptens.Type: GrantFiled: December 28, 1984Date of Patent: August 9, 1988Assignees: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche Medicale (INSERM)Inventor: Michel Geffard
-
Patent number: 4760142Abstract: Divalent hapten derivatives wherein two hapten moieties are connected by means of a bifunctional spacer wherein the derivative has the formulaA--X--Awhere A is a bonded hapten moiety and X is a bifunctional spacer having the formula(B).sub.m --Y--(CH.sub.2).sub.n --Z--(CH.sub.2).sub.n --Y--(B).sub.mwhere m is independently 0 or 1, B is (CH.sub.2).sub.n', wherein n' is an integer from 1 to 4, or CO(CH.sub.2).sub.n", wherein n" is an integer from 2 to 4; Y is independently --CONH--, NHCO--, OOC--, --COO--, --O--, --S--, or --NR--, wherein R is hydrogen or alkyl; n is an integer from 1 to 10; and Z is an organic moiety containing at least one hydrophilic atom are disclosed.Type: GrantFiled: July 6, 1987Date of Patent: July 26, 1988Assignee: Hoechst Celanese CorporationInventors: Kathleen J. Primes, Gerald F. Sigler, Gerd Grenner, Wolfgang Kapmeyer
-
Patent number: 4757003Abstract: A process for the detection of cancer comprises an immunological assay of a glycolipid present in blood, thoracic cavity fluid, abdominal dropsy or urine wherein the glycolipid can be any one selected from the group consisting of:(1) asialo GM.sub.1 : galactosyl-N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide;(2) asialo GM.sub.2 : N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide;(3) fuco GA.sub.1 : fucosyl-galactosyl-N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide; and(4) paragloboside: galactosyl-N-acetylglucosaminyl-galactosyl-glucosyl-ceramide.These glycolipids have been found to increase in body fluids with a proliferation of cancer cells.Type: GrantFiled: May 8, 1986Date of Patent: July 12, 1988Assignee: Dainabot Co., Ltd.Inventors: Makoto Matsumoto, Takao Taki, Kenji Arai, Hidemi Ishikawa, Kunio Kurata, Kiyoshi Sekiguchi, Akio Myoga, Kimimichi Obata
-
Patent number: 4740476Abstract: A process for producing an antibody having a specificity to estriol-3-sulfate, which comprises administering a 6-substituted-estriol-3-sulfate protein conjugate of the formula: ##STR1## wherein A is .dbd.N--O-- or --O--CO--, n is an integer of 1 to 4 and --NH--P is the residue of a protein excluding a hydrogen atom in the amino form therefrom parenterally to a living body of a vertebrate animal so as to produce the antibody in the living body and collecting a body fluid comprising the antibody from the living body.Type: GrantFiled: October 21, 1985Date of Patent: April 26, 1988Assignee: Nihon Medi-Physics Co., Ltd.Inventors: Akiko Kubodera, Touichi Tanaka
-
Patent number: 4737453Abstract: Immunoassay system for determining the amount of a polyvalent ligand in a liquid test sample, and based on:(a) an insoluble phase to which is bound a separation specific binding substance which does not bind said ligand;(b) a capture specific binding substance which specifically binds said ligand, and which is itself specifically bound by said spearation specific binding substance; and(c) a probe specific binding substance which specifically binds said ligand at a site which is accessible when said ligand is bound to said capture specific binding substance, said probe specific binding substance being not substantially bound by said separation specific binding substance, and being detectable by at lease one detection procedure.Type: GrantFiled: December 12, 1984Date of Patent: April 12, 1988Assignee: Immunomedics, Inc.Inventor: Frederick J. Primus
-
Patent number: 4717657Abstract: To determine whether a patient will react adversely when injected intravenously with an iodine-containing contrast media, a sample of the patient's whole blood, whole blood depleted of red blood cells or plasma is treated to activate complement, and the level of at least one product resulting from complement activation is quantified and compared to the level of that product obtained in patients of known reactivity to radiographic contrast media.Type: GrantFiled: July 17, 1985Date of Patent: January 5, 1988Assignee: E. R. Squibb & Sons, Inc.Inventors: Stephen M. Eaton, Horng-Mou Tsay, James J. Hagan, Frederick J. Yost
-
Patent number: 4665018Abstract: Human cancer is diagnosed/monitored by measuring the levels of certain modified nucleosides, such as N-[(.beta.-D-ribofuranosyl)purin-6-ylcarbamoyl]-L-threonine, in the urine of a subject by a quantitative immunoassay that preferably employs a monoclonal anti-modified nucleoside antibody and comparing that level to the level of the modified nucleoside that occurs in the urine of normal subjects to determine whether the former is substantially elevated over the latter or by comparing that level to the level of the modified nucleoside present in urine specimens taken from the subject at different times.Type: GrantFiled: September 16, 1983Date of Patent: May 12, 1987Assignee: SRI InternationalInventor: Barbara S. Vold
-
Patent number: 4659678Abstract: A method of immunoassay of an antigen in a liquid sample wherein a complex is formed between antigen contained in the said sample and two or more antibody reagents, and the said complex is bound to a solid support by non-covalent bonding as defined herein; and the amount of complex becoming bound to the support is determined; the process employing at least one monoclonal antibody reagent. Labelling methods including radio-active, fluorimetric and enzyme labelling may be used to effect determination of the binding of the complex to the solid support. The solid support may take the form of particles, beads, wall-coatings on the reaction vessel or an insert of large surface area. The method is particularly applicable to the assay of TSH, CEA, HCG, alphafeto protein, immunoglobulins, viruses, allergens, bacteria, toxins, drugs and vitamins. Use of monoclonal reagents improves the specificity of the process, and also decreases non-specific binding.Type: GrantFiled: September 26, 1983Date of Patent: April 21, 1987Assignee: Serono Diagnostics LimitedInventors: Gordon C. Forrest, Philip R. P. Salacinski, Kenneth Siddle
-
Patent number: 4650771Abstract: Immunogens for preparing antibodies against the drug lidocaine and related compounds, labeled conjugates, synthetic intermediates, and the use of such antibodies and labeled conjugates in immunoassays for determining lidocaine and such related compounds. The immunogens comprise lidocaine or an analog thereof coupled through one of the aromatic methyl groups to a conventional immunogenic carrier. The antibodies and labeled conjugates are particularly useful in homogeneous nonradioisotopic immunoassays for measuring lidocaine or its analogs in biological fluids such as serum.Type: GrantFiled: November 4, 1983Date of Patent: March 17, 1987Assignee: Miles Laboratories, Inc.Inventors: Robert T. Buckler, John F. Burd, Stephan G. Thompson
-
Patent number: 4639420Abstract: An immunoassay is provided for cholesterol epoxide. To prepare the antibodies used in the immunoassay, novel immunogens, are prepared which comprise a 3,5(6)-transdiaxial-dihydroxycholestane-6(5)-yl-hapten adduct linked to a covalently bonded bridge to a carrier protein. To detect cholesterol epoxide in the sample, it is converted to the hapten adduct, then contacted with the selected antibody.Type: GrantFiled: November 21, 1984Date of Patent: January 27, 1987Inventor: Carl P. Schaffner
-
Patent number: 4636478Abstract: Monoclonal antibodies specific for thyroxine (T.sub.4) are produced by two new and separate hybridoma cell lines. Combinations of the monoclonal antibodies from the two cell lines are used in an immunoassay for T.sub.4 of high accuracy over the range of T.sub.4 concentrations encountered in serum samples.Type: GrantFiled: July 16, 1984Date of Patent: January 13, 1987Assignee: Becton, Dickinson and CompanyInventors: Gary R. Siebert, Jean Armstrong
-
Patent number: 4634682Abstract: Radioimmunossays for the quantitation of serum thymic factor (FTS), a thymic peptide hormone, are disclosed. Each assay employs an antibody specific for FTS, the monoclonal antibody or the antibody from the antiserum of a host animal; synthetic FTS or FTS analogue as the hormone standard; and a radiolabeled FTS analogue as the tracer. Also disclosed is a method of treating serum or other biological fluid prior to assay of FTS to remove interfering substances.Type: GrantFiled: May 23, 1985Date of Patent: January 6, 1987Assignee: Sloan-Kettering Institute for CancerInventors: Bruce W. Erickson, Kam-Fook Fok, Genevieve S. Incefy, Kazuhiro Ohga
-
Patent number: 4629692Abstract: An immunoassay method and reagent system for determining nonenzymatically glucosylated proteins and protein fragments in a biological fluid based on the specific binding of such proteins and fragments with anti(Amadori-rearranged glucose), e.g., antibodies which selectively recognize the rearranged deoxyfructose form of glucose resulting when proteins are nonenzymatically glucosylated. The antibodies are raised against an immunogen comprising an immunogenic carrier material bearing 1-deoxy-1-fructosyl residues or conformers of such residues. Measurement of nonenzymatically glucosylated proteins and fragments thereof provides a useful index of blood glucose levels.Type: GrantFiled: December 6, 1982Date of Patent: December 16, 1986Assignee: Miles Laboratories, Inc.Inventor: Kenneth J. Dean
-
Patent number: 4621048Abstract: The invention relates to a method and novel reagents for detecting a ligand in a biological sample. In the method, the sample is combined with (i) an enzyme or an enzyme bound to a first macromolecular compound, (ii) substrate for the enzyme, and (iii) an antibody complex comprising anti-ligand bound to anti-enzyme and a second macromolecular compound bound to either one or both of the anti-ligand and anti-enzyme. The activity of the enzyme varies as a function of the unknown amount of ligand contained in the biological sample.Type: GrantFiled: March 12, 1984Date of Patent: November 4, 1986Assignee: Fujirebio Kabushiki KaishaInventors: Yoshihiro Ashihara, Hiromasa Suzuki, Yasushi Kasahara
-
Patent number: 4608336Abstract: Immunoassay method and reagent means for determining theophylline in biological fluids such as serum. The antibody employed in the method is prepared from an immunogen comprising theophylline coupled at its 9-position to an immunogenic carrier material.Type: GrantFiled: May 11, 1983Date of Patent: August 26, 1986Assignee: Miles Laboratories, Inc.Inventors: Jeffrey L. Benovic, Robert T. Buckler, John F. Burd, Thomas M. Li
-
Patent number: 4608200Abstract: Chloramphenicol derivatives are provided for use in the preparing of antigen conjugates for the production of antibodies specifically for chloramphenicol. Specifically, the aryl amino group is derivatized to introduce a non-oxo-carbonyl group which is used for amide formation with an antigen. The conjugate is then injected into a vertebrate for production of antisera which is isolated in conventional ways and find particular use in competitive protein binding assays.Type: GrantFiled: November 30, 1984Date of Patent: August 26, 1986Assignee: Syntex (U.S.A.) Inc.Inventors: Pyare L. Khanna, Evan S. Snyder, Prithipal Singh
-
Patent number: 4596768Abstract: Conjugates of penicilloic acid derivatives and certain poly(amino acids), which are either antigenic or enzymatic, are provided. Antibodies raised against the antigenic poly(amino acids) and the enzyme conjugates are used as reagents in immunoassays. In particular, the compounds of the present invention can be used for measuring the presence of a .beta.-lactamase in a patient serum sample by adding a known amount of penicillin to the sample and observing the production of penicilloic acid over a fixed period of time.Type: GrantFiled: November 2, 1983Date of Patent: June 24, 1986Assignee: Syntex (U.S.A.) Inc.Inventors: Prithipal Singh, Danton K. Leung, Richard Rodgers
-
Patent number: 4596771Abstract: A continuous hybridoma cell line which secretes recoverable quantities of monoclonal antibodies having specificity against Vitamin B.sub.6, which antibodies are useful in a method for detecting the presence of vitamin B.sub.6 in an animal sample.Type: GrantFiled: May 23, 1984Date of Patent: June 24, 1986Assignee: Research CorporationInventors: John A. Cidlowski, Dace Viceps-Madore
-
Patent number: 4591573Abstract: A sensitive and specific radioimmunoassay is developed for L-hyoscyamine ulting from atropine administration with which a concentration as low as 25 pg/ml using 0.1 ml of sample can be measured without the need for extraction. Specificity studies indicate that an antibody according to this invention has high specific recognition of L-hyoscyamine with only about 37% cross reaction with the D-hyoscyamine enantiomer of atropine. The antibody is produced from an immunogen having conjugated at least 42 and preferably 45 L-hyoscyamine-p-aminobenzoic acid haptenic molecules per molecule of bovine serum albumin. An antibody according to this invention can be used with a dilution titer as high as 1:2000.Type: GrantFiled: September 23, 1983Date of Patent: May 27, 1986Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Pritam S. Verma
-
Patent number: 4585740Abstract: A peptide having the formula ##STR1## is synthesized. The peptide is conjugated, e.g., with bis-diazotized benzidine, at its C-terminus to a carrier, such as bovine serum albumin, to form a synthetic antigen useful for inducing antibody production in a host animal. The antiserum obtained from the host animal is free of cross-reactivity with other pituitary substances and thus particularly advantageous for assay purposes. The peptide, whether unlabeled or labeled with radioactive iodine on the tyrosine moiety, has an affinity to antiserum raised against the conjugate similar to the affinity of natural hPRL to the antiserum. The synthetic peptide is used in radioimmunoassays where the labeled peptide competes for the binding sites in the antiserum with unknown concentrations of hPRL in biological samples.Type: GrantFiled: May 3, 1983Date of Patent: April 29, 1986Assignee: The Whittier Institute for Diabetes and EndocrinologyInventor: Willard P. VanderLaan
-
Patent number: 4565696Abstract: Enhanced immunogenicity is achieved by covalently linking immunogens to liposomes and injecting the membrane-bound-proteins into an appropriate vertebrate host. Methods and compositions are provided for producing antibodies.Type: GrantFiled: August 3, 1983Date of Patent: January 21, 1986Assignee: The Regents of the University of CaliforniaInventors: Timothy D. Heath, Pang Shek, Demetrios Papahadjopoulos
-
Patent number: 4543325Abstract: The present invention provides a process for the immunological determination of creatinine, wherein creatinine is converted into 1-methylhydantoin, the 1-methylhydantoin formed is incubated in an aqueous medium with antibodies which are directed against a conjugate of a first hydantoin derivative of the general formula: ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4, which can be the same or different, are hydrogen atoms, alkyl radicals containing up to 3 carbon atoms or phenyl radicals, with a first hapten carrier substance suitable for antibody formation, reacted with a conjugate of a second hydantoin derivative of general formula (I) with a second hapten carrier substance, one of the components antibody and conjugate being present in the solid phase or in dissolved form and the other component being present in dissolved form, and the inhibition of the binding reaction between the antibodies and the hydantoin conjugate with the second hapten carrier substance is measured.Type: GrantFiled: December 15, 1982Date of Patent: September 24, 1985Assignee: Boehringer Mannheim GmbHInventors: Winfried Albert, Joachim Ziegenhorn, Joachim Siedel, Hans-Georg Batz, Helmut Lenz, Brigitte Pautz
-
Patent number: 4504585Abstract: An affinity immunoassay system in which a solid phase nonimmunological, group-specific ligand is used to insolubilize the analyte of interest either simultaneously, before or after binding all of the analyte with a labelled monospecific antibody and the concentration of the analyte is then determined by measuring the label activity present in the solid phase in relation to a single point calibrator solution containing a known amount of the analyte substance.Type: GrantFiled: April 5, 1982Date of Patent: March 12, 1985Assignee: Aalto Scientific, Ltd.Inventor: Robert A. Reynolds
-
Patent number: 4495296Abstract: A process for detecting the presence of an antigen in a specimen is described, which process comprises:(A) contacting said specimen with a substrate coated with antibodies of said antigen, incubating the contacted substrate and washing the substrate;(B) contacting the washed material of step (A) with a hapten conjugated antibody against said antigen, incubating the so-contacted material and washing the so-incubated material;(C) contacting the washed material of step (B) with a radioactive material labeled or enzyme containing anti-hapten antibody, incubating the so-contacted material and washing the same; and(D) effecting radioimmunoassay if said antibody is radioactive or enzyme labeled immunoassay if said antibody contains an enzyme moiety.Quantitative determination of the antigen in the specimen is effected by comparing the counts of the radioimmunoassay or the concentration of enzyme against a standard as by photocolormetric methods.Type: GrantFiled: May 21, 1979Date of Patent: January 22, 1985Assignee: New York Blood Center, Inc.Inventors: A. Robert Neurath, Nathan Strick
-
Patent number: 4490473Abstract: Sandwich immunoassays are provided wherein an anti-analyte antibody is coupled with a detector labeled antibody, the anti-analyte antibody being substituted with a N,N,N-trimethylammoniumphenyl group and the detector labeled antibody is an antibody specific to the N,N,N-trimethylammoniumphenyl group. The invention includes novel assays, antigens and antibodies.Type: GrantFiled: March 28, 1983Date of Patent: December 25, 1984Assignee: PanAbInventor: Robert F. Brunhouse
-
Patent number: 4456691Abstract: A polychlorinated biphenyl hapten is covalently bonded to a macromolecule carrier through a diazo-containing linking group. In forming the conjugate, a PCB hapten is nitrated, aminated, diazotized and finally coupled with the macromolecule carrier. The antigen may be used to raise antibodies specific to the hapten and binding with the hapten.Type: GrantFiled: February 28, 1983Date of Patent: June 26, 1984Inventor: Suad Stark
-
Patent number: 4427780Abstract: Vitamin-containing multicomponent compositions are assayed to determine the extent of conversion of the vitamin to one or more analogues thereof due to interaction between the vitamin and the other components of the composition, employing a radioactive labeled form of the vitamin. The assay is useful for quality control in the manufacture of multivitamin and multivitamin-mineral formulations and vitamin-supplemented foods intended for human or animal ingestion.Type: GrantFiled: August 13, 1981Date of Patent: January 24, 1984Assignee: University Patents, Inc.Inventor: Robert H. Allen
-
Patent number: 4407965Abstract: A process for preparing a gut glucagon antigen composed of a peptide-carrier complex is disclosed, which comprises using as hapten a peptide represented by the following general formula;R-Lys-Arg-Asn-Lys-Asn-Asn-Ile-Ala-OHwherein R represents a hydrogen atom, an amino acid group or a peptide group containing 2 to 20 amino acid groups, and reacting it with a carrier in the presence of a binding agent for binding the hapten and the carrier to each other. Also, a process for preparing a gut glucagon antibody, which comprises administering the antigen described to mammals, and collecting the thus-produced antibody, is disclosed.Type: GrantFiled: May 21, 1981Date of Patent: October 4, 1983Assignee: Otsuka Pharmaceutical Co., Ltd.Inventor: Noboru Yanaihara
-
Patent number: 4379779Abstract: A hapten is obtained by replacing the 3-hydroxy group of equilin with HO--CO--A--O-- wherein A is an alkylene of one to six carbon atoms. The hapten is conjugated with an immunological carrier to provide an immunogen, which in turn produces a specific antiserum to equilin. The antiserum is used in a radioimmunoassay for equilin.Type: GrantFiled: September 29, 1980Date of Patent: April 12, 1983Assignee: American Home Products CorporationInventors: Pemmaraju N. Rao, Robert H. Purdy, Perry H. Moore, Jr.
-
Patent number: 4379780Abstract: A hapten is obtained by replacing the 3-hydroxy group of 17 .alpha.-dihydroequilin with HO--CO--A--O-- wherein A is an alkylene of one to six carbon atoms. The hapten is conjugated with an immunological carrier to provide an immunogen, which in turn produces a specific antiserum to 17 .alpha.-dihydroequilin. The antiserum is used in a radioimmunoassay for 17 .alpha.-dihydroequilin.Type: GrantFiled: September 29, 1980Date of Patent: April 12, 1983Assignee: American Home Products CorporationInventor: Pemmaraju N. Rao
-
Patent number: RE31517Abstract: A method for the quantitative determination of renin activity in blood utilizing the measurement of Angiotensin I by treating the blood with ethylenediaminetetraacetic acid (EDTA) and the plasma with phenylmethyl sulfonylfluoride (PMSF) at a preferred pH to ascertain the full range of concentration where PMSF is effective for accurate and quick determination.Also, a method for the quantitative determination of renin activity in blood utilizing the measurement of Angiotensin I by incubating the samples after antibody addition at room temperature (23.degree. to 30.degree. C.) for 1 to 2 hours and separating the free from the antibody bound species with polyethylene glycol after having treated the blood with ethylenediaminetetraacetic acid (EDTA) and the plasma with phenylmethyl sulfonylfluoride (PMSF) at a preferred pH.Type: GrantFiled: September 15, 1978Date of Patent: February 7, 1984Inventor: Aurora L. Fernandez de Castro